Watch out Sanofi: Takeda's new da­ta on dengue vac­cine is good news for PhI­II tri­al

Prospects for Take­da’s dengue vac­cine just turned brighter fol­low­ing fresh da­ta from the com­pa­ny’s Phase II tri­al. For Take­da, the da­ta is like­ly wel­come con­sid­er­ing the com­pa­ny al­ready has a mas­sive piv­otal tri­al un­der­way for the vac­cine. For com­peti­tor Sanofi … per­haps not so wel­come.

The da­ta show Take­da’s vac­cine, called TAK-003, for­ti­fied the im­mune sys­tems of pa­tients for 18 months by boost­ing an­ti­bod­ies that fight the virus. The vac­cine was al­so well-tol­er­at­ed. For the tri­al, Take­da is test­ing 1,794 chil­dren and ado­les­cents liv­ing in re­gions prone to dengue out­break.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER